Literature DB >> 28561276

Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.

Benjamin Heidrich1,2,3, Marius Vital2, Iris Plumeier2, Nico Döscher1, Silke Kahl2, Janina Kirschner1, Szilvia Ziegert1, Philipp Solbach1, Henrike Lenzen1, Andrej Potthoff1, Michael Peter Manns1,3, Heiner Wedemeyer1,3, Dietmar Helmut Pieper2.   

Abstract

BACKGROUND & AIMS: The importance of the intestinal microbiota for the onset and clinical course of many diseases, including liver diseases like non-alcoholic steatohepatitis and cirrhosis, is increasingly recognized. However, the role of intestinal microbiota in chronic hepatitis C virus (HCV) infection remains unclear.
METHODS: In a cross-sectional approach, the intestinal microbiota of 95 patients chronically infected with HCV (n=57 without cirrhosis [NO-CIR]; n=38 with cirrhosis [CIR]) and 50 healthy controls (HC) without documented liver diseases was analysed.
RESULTS: Alpha diversity, measured by number of phylotypes (S) and Shannon diversity index (H'), decreased significantly from HC to NO-CIR to CIR. S and H' correlated negatively with liver elastography. Analysis of similarities revealed highly statistically significant differences in the microbial communities between HC, NO-CIR and CIR (R=.090; P<1.0×10-6 ). Stratifying for HCV genotypes even increased the differences. In addition, we observed distinct patterns in the relative abundance of genera being either positive or negative correlated with diseases status.
CONCLUSIONS: This study shows that not only the stage of liver disease but also HCV infection is associated with a reduced alpha diversity and different microbial community patterns. These differences might be caused by direct interactions between HCV and the microbiota or indirect interactions facilitated by the immune system.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alpha diversity; cirrhosis; gut microbiome; liver elastography; microbial diversity

Mesh:

Year:  2017        PMID: 28561276     DOI: 10.1111/liv.13485

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  27 in total

1.  The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?

Authors:  Eric G Meissner
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

Review 2.  Gut Barrier and Microbiota in Cirrhosis.

Authors:  Cyriac A Philips; Philip Augustine
Journal:  J Clin Exp Hepatol       Date:  2021-09-03

3.  Microbial Translocation in the Context of Hepatitis B Infection and Hepatitis D Infection.

Authors:  Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Pallavi Surana; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Meital Gewirtz; James A Haddad; David E Kleiner; Christopher Koh; Theo Heller
Journal:  Open Forum Infect Dis       Date:  2020-10-20       Impact factor: 4.423

4.  Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.

Authors:  Natthaya Chuaypen; Thananya Jinato; Anchalee Avihingsanon; Sakkarin Chirapongsathorn; Supapon Cheevadhanarak; Intawat Nookaew; Yasuhito Tanaka; Pisit Tangkijvanich
Journal:  J Infect Dis       Date:  2021-10-28       Impact factor: 5.226

Review 5.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

Review 6.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

Review 7.  Role of Gut Microbiota in Hepatocarcinogenesis.

Authors:  Haripriya Gupta; Gi Soo Youn; Min Jea Shin; Ki Tae Suk
Journal:  Microorganisms       Date:  2019-05-05

Review 8.  The Role of the Microbiome in Liver Cancer.

Authors:  Mar Moreno-Gonzalez; Naiara Beraza
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

9.  Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis.

Authors:  I Jane Cox; Ramazan Idilman; Andrew Fagan; Dilara Turan; Lola Ajayi; Adrien D Le Guennec; Simon D Taylor-Robinson; Fatih Karakaya; Edith Gavis; R Andrew Atkinson; Roger Williams; Masoumeh Sikaroodi; Shahzor Nizam; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Liver Int       Date:  2019-10-07       Impact factor: 8.754

Review 10.  Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.

Authors:  Wei Jia; Cynthia Rajani; Hongxi Xu; Xiaojiao Zheng
Journal:  Protein Cell       Date:  2020-08-14       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.